StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Adagio Therapeutics (ADGI) Stock Now Up 70%, Stifel Says Merck's (MRK) Molnupiravir is not a Competitive Threat to ADG20
November 29, 2021 11:08 AM
Adagio Therapeutics (NASDAQ: ADGI) stock is up around 70% today as investors continue to bet that alternative cures are needed ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Momentum Movers
Trader Talk
Next Articles
Adagio Therapeutics (ADGI) Climbs 60%
November 30, 2021 9:53 AM
Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma
November 30, 2021 6:45 AM
Adagio Therapeutics (ADGI) Shares Are Up 80% Since Friday. Here's Why
November 29, 2021 7:38 AM